IMPI

Bio-Path Holdings Expands Global Patent Portfolio

Retrieved on: 
Monday, April 15, 2024
Investment, IMPI, BCL2, Holding, STAT3, IP Australia, Patent, Patient, Dicarboxylic acid, 3D printing

Bio-Path has expanded its intellectual property portfolio by filing patent applications that are applicable to its technology and business strategy.

Key Points: 
  • Bio-Path has expanded its intellectual property portfolio by filing patent applications that are applicable to its technology and business strategy.
  • Bio-Path’s patent portfolio currently includes five issued patents in the U.S. and 54 issued patents in foreign jurisdictions, providing protection in 21 countries.
  • On this basis, Bio-Path has one additional patent application allowed in the U.S. and five additional patent applications allowed in foreign jurisdictions, for a total of six additional patent grants expected this year.
  • Further, the Company has five pending patent applications in the U.S. and 46 pending patent applications in key foreign jurisdictions across six families of applications, for a total of 51 pending applications.